A Calcium Antagonist vs a Non-Calcium Antagonist Hypertension Treatment Strategy for Patients with Coronary Artery Disease the International Verapamil-Trandolapril Study (INVEST): A Randomized Controlled Trial

JAMA

Volumn 290, Issue 21, 2003, Pages 2805-2816

  Pepine, Carl J ^a   Handberg, Eileen M ^a   Cooper DeHoff, Rhonda M ^a   Marks, Ronald G ^a   Kowey, Peter ^b   Messerli, Franz H ^c   Mancia, Giuseppe ^d   Cangiano, José L ^e   Garcia Barreto, David ^f   Keltai, Matyas ^g   Erdine, Serap ^h   Bristol, Heather A ^a   Kolb, H Robert ^a   Bakris, George L ⁱ   Cohen, Jerome D ^j   Parmley, William W ^k  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b LANKENAU HOSPITAL   (United States)

^c OCHSNER CLINIC FOUNDATION   (United States)

^d UNIVERSITY OF MILANO BICOCCA   (Italy)

^e Clinica Las Americas   (Puerto Rico)

^f Inst Cardiol Cirugia Cardiovasc   (Cuba)

^g SEMMELWEIS UNIVERSITY   (Hungary)

^h ISTANBUL UNIVERSITY   (Turkey)

ⁱ RUSH UNIVERSITY   (United States)

^j SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; CALCIUM ANTAGONIST; HYDROCHLOROTHIAZIDE; TRANDOLAPRIL; VERAPAMIL;

AGED; ALZHEIMER DISEASE; ANGINA PECTORIS; ARTICLE; ATRIOVENTRICULAR BLOCK; BLOOD PRESSURE REGULATION; BRADYCARDIA; CANCER; CAUSE OF DEATH; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; COUGHING; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DYSPNEA; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GOUT; HEADACHE; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOKALEMIA; KIDNEY DYSFUNCTION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTICENTER STUDY; PARKINSON DISEASE; PERIPHERAL EDEMA; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STROKE; SYSTOLIC BLOOD PRESSURE; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS; VERTIGO; WHEEZING;

EID: 0345492460     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.290.21.2805     Document Type: Article

References (44)

1. American Heart Association. Heart Disease and Stroke Statistics-2003 Update. Dallas, Tex: American Heart Association; 2002.
2. Chalmers J, MacMahon S, Mancia G, et al. Guidelines for the management of hypertension. Clin Exp Hypertens. 1999;21:1009-1060.
3. Hansson L, Zanchetti I, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension. Lancet. 1998;351:1755-1762.
4. Probstfield JL, for the SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA. 1991;265:3255-3264.
5. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients. Lancet. 1999;354:1751-1756.
6. Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study. Lancet. 2000;356:366-372.
7. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA. 2003;289:2560-2572.
8. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension. Lancet. 1999;353:611-616.
9. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997;157:2413-2446.
10. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145-153.
11. Hennekens CH, Albert CM, Godfried SL, Gaziano JM, Buring JE. Adjuncitve drug therapy for acute myocardial infarction-evidence from clinical trials. N Engl J Med. 1996;335:1660-1667.
12. The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 1993;153:154-183.
13. Messerli FH, Grossman E, Goldbourt U. Are β-blockers efficacious as first-line therapy for hypertension in the elderly? JAMA. 1998;279:1903-1907.
14. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint Reduction in Hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
15. Neal B, MacMahon S, Chapman N, et al. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs. Lancet. 2000;356:1955-1964.
16. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor of calcium channel blocker vs diuretic. JAMA. 2002;288:2981-2997.
17. Furberg CD, Psaty SM, Meyer JV. Nifedipine. Circulation. 1995;92:1326-1331.
18. Epstein M. The calcium antagonist controversy. Am J Cardiol. 1997;79:9-19.
19. Pepine CJ. The role of calcium antagonists in ischaemic heart disease. Eur Heart J. 1995;16(suppl H):19-24.
20. Pepine CJ, Faich G, Makuch R. Verapamil use in patients with cardiovascular disease: an overview of randomized trials. Clin Cardiol. 1998;21:633-641.
21. Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet. 2000;356:359-365.
22. Ruilope LM, de la Sierra A, Moreno E, et al. Prospective comparison of therapeutical attitudes in hypertensive type 2 diabetic patients uncontrolled on monotherapy, a randomized trial: the EDICTA study. J Hypertens. 1999;17:1917-1923.
23. Karlberg BE, Andrup M, Oden A, for the Swedish TARKA trialists. Efficacy and safety of a new long-acting drug combination, trandolapril/verapamil as compared to monotherapy in primary hypertension. Blood Press. 2000;9:140-145.
24. PROCOPA Study Group. Dissociation between blood pressure reduction and fall in proteinuria in primary renal disease. J Hypertens. 2002;20:729-737.
25. Holzgreve H, Nakov R, Beck K, Janka HU. Antihypertensive therapy with verapamil SR plus trandolapril versus atenolol plus chlorthalidone on glycemic control. Am J Hypertens. 2003;16:381-386.
26. Wing LMH, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003;348:583-592.
27. Parving HH, Lehnert H, Bröchner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870-878.
28. Brenner SM, Cooper ME, De Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
29. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med. 1998;338:645-652.
30. Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;19:2421-2431.
31. Pepine CJ, Handberg-Thurmond E, Marks RG, et al. Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST). J Am Coll Cardiol. 1998;32:1228-1237.
32. Hansson L, Hedner T, Dahlöf B. Prospective Randomized Open Blinded End-point (PROBE) study. Blood Press. 1992;1:113-119.
33. INVEST information pack. Available at: http://www.medicine.ufl.edu/cardio/research/invest-info/invest_definitions. shtml. Accessed October 4, 2003.
34. Alderman M, Arakawa K, Beilin L, et al. Effects of calcium antagonists on the risks of coronary heart disease, cancer and bleeding. J Hypertens. 1997;15:105-115.
35. Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes. Am J Kidney Dis. 2000;36:646-661.
36. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA. 1995;274:620-625.
37. Pahor M, Psaty BM, Alderman MH, et al. Health outcomes associated with calcium antagonist compared with other first-line antihypertensive therapies. Lancet. 2000;356:1949-1954.
38. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure. Lancet. 1999;353:2001-2007.
39. Dargie HJ, Lechat P. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9-13.
40. Packer M, Coats AJS, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651-1658.
41. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality. Lancet. 2002;360:1903-1913.
42. Cooper-DeHoff R, Bakris G, Cohen J, et al. Reduced risk of new onset diabetes in hypertensive coronary artery disease patients treated with a calcium antagonist vs a beta blocker regimen: the International Verapamal/Trandolapril Study. Circulation. 2003;108:IV-750.
43. Wright J, Davis B, Cutler J, et al. Long-term cardiovascular consequences of diuretics vs calcium channel blockers vs angiotensin-converting enzyme inhibitors. JAMA. 2003;289:2067-2069.
44. Bengtsson C, Blohme G, Lapidus L, Lissner L, Lundgren H. Diabetes incidence in users and non-users of antihypertensive drugs in relation to serum insulin, glucose tolerance and degree of adiposity. J Intern Med. 1992;231:583-588.